

CERTIFICATE OF ANALYSIS

Page 1 of 3

Cell Line Details

Product code: HEP-003-AAT-z

Product name: iPSC-derived Human Hepatocytes: CRISPR-engineered Homozygous Alpha-1 Antitrypsin Deficiency E342K

Lot number: XXXXXX

Storage conditions: Store at less than -130°C

QC completion date: XXXXXX

Cell Quality Controls

Test	Method	Specification	Result
Virus test for original iPSC clone (HIV1, HIV2, Hepatitis A, HBV, HCV, HTLV-1, HTLV-2)	PCR	Not detected	Pass
Post thaw viability	Automated cell counter	≥ 70% viable	Pass
Viable cells per vial	Automated cell counter	≥ 5.0 x 10 ⁶	Pass
Cell morphology	Visual check	N/A	Pass (Fig.1)
Key hepatocyte maturity markers (<i>ALB</i> , <i>A1AT</i> , <i>HNF4a</i>)	qPCR	Present	Pass (Fig.2)
Disease markers (intracellular polymeric A1AT)	ELISA	≥ 3.0 (fold change over WT)	Pass (Fig.3)
Disease confirmation	Sanger sequencing	Mutation present	Pass (Fig.4)

DefiniGEN Limited

Babraham Research Campus, Babraham,
 Cambridge, CB22 3AT, UK
info@definigen.com
 © 2023 DefiniGEN Limited

www.definigen.com


CERTIFICATE OF ANALYSIS

Page 2 of 3

Appendix


1. Cell morphology

Figure 1. Morphology of cryopreserved hepatocyte-like cells, 14 days post-thaw. Brightfield picture, magnification: 100x.




2. Detection of hepatocyte maturity markers via qPCR

Figure 2. mRNA expression of the key hepatocyte maturity markers *ALB* (Albumin), *A1AT* (Alpha-1 Antitrypsin) and *HNF4A* (Hepatocyte Nuclear Factor-4) in cryopreserved hepatocyte-like cells (black bars) and primary human hepatocytes (PHH, grey bars), 14 days post-thaw. mRNA data are normalized to endogenous *PPIA* expression, and are presented as mean \pm SD of n=3 technical replicates.



3. Detection of intracellular A1AT polymers via ELISA

Figure 3. Intracellular polymers detected by 2C1 ELISA 14 days post-thaw. The graph shows relative values, calculated by normalizing A1AT polymer content (ng/ml) to total protein in each cell lysate. Data normalized to wild type isogenic control (HEP-003), set as 1.



DefiniGEN Limited

Babraham Research Campus, Babraham,
 Cambridge, CB22 3AT, UK

info@definigen.com


© 2023 DefiniGEN Limited

www.definigen.com

CERTIFICATE OF ANALYSIS

Page 3 of 3

4. Disease confirmation via Sanger sequencing



Ref Seq 301 G C C T T A C A A C G T G T C T C T G C T T C T C T C C C C T C C A G G C C G T G C A T A A G G C T G T G C T G A C C A T C G A C G A G A A A G G G A C T G A A G C T G C T G G G G C C A T G T T T T T 400

HEP-003-AAT-z 67 G C C T T A C A A C G T G T C T C T G C T T C T C T C C C C T C C A G G C C G T G C A T A A G G C T G T G C T G A C C A T C G A C A A G A A A G G G A C T G A A G C T G C T G G G G C C A T G T T T T T 166

Figure 4. Sanger sequencing showing homozygous E342K mutation (GAG > AAG) in the *SERPINA1* gene. The codon change is highlighted in yellow. The wild type sequence (Ref Seq) is shown at the top while the mutant line at the bottom.

Checked by,

signature

QC Scientist

DefiniGEN Limited

Babraham Research Campus, Babraham,
 Cambridge, CB22 3AT, UK

info@definigen.com

© 2023 DefiniGEN Limited

www.definigen.com